Clinical trial · Interventional
Latisse (Bimatoprost .03% Opthalmic Solution) for the Treatment of Hypotrichosis of the Eyebrows: Latisse Versus Placebo
Latisse(Bimatoprost .03% Opthalmic Solution) for the Treatment of Hypotrichosis of the Eyebrows: Latisse Versus Placebo
NCT01387906CI-TRIAL-00007206completedPhase 4ClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
The primary purpose of this study is to assess efficacy and safety of Latisse (bimatoprost .03% ophthalmic solution) applied to the lateral and medial eyebrows. The primary outcome is a increase in overall eyebrow prominence as measured by at least a 1-grade increase on the Global Eyebrow Assessment (GEyA) scale, from baseline to the end of the treatment which will be day 270 period.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Hypotrichosis | — | UNRESOLVED | — |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| topical bimatoprost | Drug | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- type
- EXPERIMENTAL
- label
- Topical bimatoprost for eyebrows
- description
- Topical bimatoprost will be applied to areas of the eyebrow that have diminished eyebrows (hypotrichosis).
- interventionNames
- Drug: topical bimatoprost
Primary outcomes (1)
- measure
- Efficacy of Latisse applied to the lateral and medial eyebrow
- timeFrame
- 10 months
- description
- Increase in overall eyebrow prominence as measured by at least a 1-grade increase on the Global Eyebrow Assessment (GEyA) scale, from baseline to the end of the treatment which will be day 270 period.
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
- Maximum age
- 75 Years
Show eligibility criteria text
Inclusion Criteria: * Outpatient, female/male subjects of any race, 18-75 years of age. * Subjects of childbearing potential must have a negative urine pregnancy test result at Baseline and practice a reliable method of contraception throughout the study * Patients with hypotrichosis (thinning) of the eyebrows with a GEyA score of 1 or 2. * Patient agrees to abstain from any treatment to the eyebrows including: waxing, plucking, threading, laser hair removal, and/or bleaching (excluding the glabella region). * Able to understand the requirements of the study and sign Informed Consent/HIPAA Authorization forms. * Written informed consent and written authorization for use or release of health and research information obtained. * Willing to complete all required study visits, procedures, and evaluations including photography. Exclusion Criteria: * Subjects who are pregnant (positive urine pregnancy test), planning to become pregnant, breast-feeding, or who are of childbearing potential and not practicing a reliable method of birth control. * Patients with any uncontrolled systemic disease * Patient with any known disease or abnormality of the eyebrows including eczema and seborrheic dermatitis * Patients with known or suspected trichotillomania disorder * Patients with a history of glaucoma and/or increased ocular pressure * Patients who are currently using an IOP-lowering prostaglandin analog (including Lumigan) * Patients with a known hypersensitivity to bimatoprost or any other ingredient in Latisse * Previous cosmetic surgery to the upper face (e.g., periorbital surgery, brow lift, eyelid or eyebrow surgery, etc.). * Patients with permanent eye and/or eyebrow make-up * Any eyebrow tint or dye applications within 2 months prior to study entry * Any planned facial cosmetic procedure that would interfere with the evaluation of the eyebrows * Participation in another investigational drug or device study within the last 30 days
References
Publications (2)
- BACKGROUNDLaw SK. Bimatoprost in the treatment of eyelash hypotrichosis. Clin Ophthalmol. 2010 Apr 26;4:349-58. doi: 10.2147/opth.s6480. PMID 20463804
- BACKGROUNDBimatoprost 0.03% solution (latisse) for eyelash enhancement. Med Lett Drugs Ther. 2009 Jun 1;51(1313):43-4. No abstract available. PMID 19478690